Cresset Asset Management LLC Sells 19,929 Shares of Artivion, Inc. (NYSE:AORT)

Cresset Asset Management LLC decreased its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 52.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,130 shares of the company's stock after selling 19,929 shares during the quarter. Cresset Asset Management LLC's holdings in Artivion were worth $518,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of AORT. Smartleaf Asset Management LLC raised its holdings in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after purchasing an additional 786 shares during the last quarter. R Squared Ltd purchased a new position in shares of Artivion in the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new position in shares of Artivion in the fourth quarter valued at approximately $43,000. Venturi Wealth Management LLC purchased a new stake in shares of Artivion during the 4th quarter valued at $78,000. Finally, KBC Group NV increased its position in shares of Artivion by 80.4% during the 4th quarter. KBC Group NV now owns 2,813 shares of the company's stock valued at $80,000 after purchasing an additional 1,254 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 10,548 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $29.13, for a total value of $307,263.24. Following the completion of the transaction, the senior vice president now owns 105,332 shares of the company's stock, valued at $3,068,321.16. The trade was a 9.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Lance A. Berry sold 3,259 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $89,003.29. Following the sale, the chief financial officer now owns 75,805 shares in the company, valued at $2,070,234.55. The trade was a 4.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 101,347 shares of company stock valued at $2,663,486 in the last 90 days. Corporate insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AORT shares. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Finally, JMP Securities reissued a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $31.40.

Artivion Price Performance

Shares of AORT traded down $0.43 during midday trading on Tuesday, hitting $29.29. 47,184 shares of the company traded hands, compared to its average volume of 321,733. The stock has a 50-day moving average of $24.76 and a 200-day moving average of $27.33. The firm has a market cap of $1.25 billion, a P/E ratio of -1,465.25 and a beta of 1.54. Artivion, Inc. has a one year low of $21.97 and a one year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million during the quarter, compared to analysts' expectations of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, sell-side analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.